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A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic[^1^](#ana25770-bib-0001){ref-type="ref"} is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of contracting SARS‐CoV‐2 and more severe disease. The Society of Italian Neurologists (SIN) and the Association of British Neurologists (ABN) MS and Neuroimmunology Advisory Group published guidance for the use of disease modifying treatments (DMTs) in MS (Table [1](#ana25770-tbl-0001){ref-type="table"}).[^2^](#ana25770-bib-0002){ref-type="ref"} However, taking into account less conservative viewpoints,[^3^](#ana25770-bib-0003){ref-type="ref"} the emerging knowledge of the biology of SARS‐CoV‐2, and, in particular, the role of the immune mechanisms contributing to the disease, we propose modification of these guidelines because it is not clear that immunosuppression is indeed detrimental in people with MS infected with SARS‐CoV‐2. Thus, we are proposing a more nuanced approach and that the categories of DMTs should be modified based on scientific principles and the biology of severe coronavirus disease 2019 (COVID‐19; Table [2](#ana25770-tbl-0002){ref-type="table"}).

###### 

SIN and the ABN Guidelines for the DMTs in use for MS during the COVID‐19 Pandemic[^2^](#ana25770-bib-0002){ref-type="ref"}

  At risk category                                Class                Trade name                           Safe to start treatment   On treatment   COVID‐19 infection   Mode of action
  ----------------------------------------------- -------------------- ------------------------------------ ------------------------- -------------- -------------------- ---------------------------------------------------------------------------------------------------
  Low                                             Interferon‐Beta      Betaferon, Avonex, Rebif, Plegridy   Yes                       Continue       Stop                 Immunomodulatory (not immunosuppressive), pleiotropic immune effects
  Low                                             Glatiramer acetate   Copaxone                             Yes                       Continue       Stop                 Immunomodulatory (not immunosuppressive), pleiotropic immune effects
  Low                                             Teriflunomide        Aubagio                              Yes                       Continue       Stop                 Dihydro‐orotate dehydrogenase inhibitor (reduced de novo pyrimidine synthesis), antiproliferative
  Low                                             Dimethyl fumarate    Tecfidera                            Yes                       Continue       Stop                 pleiotropic, NRF2 activation, downregulation of nfκβ
  Low                                             Natalizumab          Tysabri                              Yes                       Continue       Stop                 Anti‐VLA4, selective adhesion molecule inhibitor
  Low                                             S1P modulators       Fingolimod (Gilenya)                 Yes                       Continue       Stop                 Selective S1P modulator, prevents egress of lymphocytes from lymph nodes
  Intermediate                                    Anti‐CD20            Ocrelizumab (Ocrevus)                No (Yes)                  Suspend        Delay                Anti‐CD20, B‐cell depleter
  High[^a^](#ana25770-note-0002){ref-type="fn"}   Cladribine           Mavenclad                            No                        Suspend        Delay                Deoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T and B cell depletion
  High[^a^](#ana25770-note-0002){ref-type="fn"}   Alemtuzumab          Lemtrada                             No                        Suspend        Delay                Anti‐CD52, nonselective immune depleter
  High[^a^](#ana25770-note-0002){ref-type="fn"}   HSCT                 --                                   No                        --             Delay                Non‐selective immune depleter

Risk refers to acquiring infection during the immunodepletion phase. With postimmune reconstitution, the risk is low.

ABN = Association of British Neurologists; COVID‐19 = coronavirus disease 2019; DMT = disease modifying treatment; MS = multiple sclerosis; SIN = Society of Italian Neurologists.

Modified from Coles et al.[^2^](#ana25770-bib-0002){ref-type="ref"}

###### 

Proposed Revised Guidelines

  At risk category                                Class                                      Trade Name                                                      Safe to start treatment   Advice regarding treatment                     COVID‐19 infection
  ----------------------------------------------- ------------------------------------------ --------------------------------------------------------------- ------------------------- ---------------------------------------------- ----------------------------------------------------
  Very low                                        Interferon‐beta                            Betaferon, Avonex, Rebif, Plegridy                              Yes                       Continue                                       Continue
  Very low                                        Glatiramer acetate                         Copaxone                                                        Yes                       Continue                                       Continue
  Very low                                        Cladribine/Alemtuzumab/Mitoxantrone/HSCT   see below                                                       N/A                       N/A                                            N/A
  Very low                                        Teriflunomide                              Aubagio                                                         Yes                       Continue                                       Continue
  Low                                             Dimethyl fumarate                          Tecfidera                                                       Probably                  Continue/Switch if lymphopenia                 Continue
  Low                                             Natalizumab (EID)                          Tysabri                                                         Yes                       Continue                                       Continue or miss infusion depending on timing
  Low                                             Anti‐CD20                                  Ocrelizumab (Ocrevus), Ofatumumab, Rituximab, Ublituximab       Probably                  Risk assessment ‐ continue or suspend dosing   Temporary suspension of dosing depending on timing
  Intermediate                                    Cladribine                                 Mavenclad                                                       Probably                  Risk assessment ‐ continue or suspend dosing   Temporary suspension of dosing depending on timing
  Intermediate                                    S1P modulators                             Fingolimod (Gilenya), Siponimod (Mazent), Ozanimod, Ponesimod   Probably                  Continue                                       Continue or temporary suspension of dosing
  Intermediate                                    Natalizumab (SID)                          Tysabri                                                         Yes                       Continue, but consider EID                     Continue or miss infusion depending on timing
  High[^a^](#ana25770-note-0005){ref-type="fn"}   Mitoxantrone                               Novatrone                                                       No                        Suspend dosing                                 Suspend dosing
  High[^a^](#ana25770-note-0005){ref-type="fn"}   Alemtuzumab                                Lemtrada                                                        No                        Suspend dosing                                 Suspend dosing
  High[^a^](#ana25770-note-0005){ref-type="fn"}   HSCT                                       --                                                              No                        Suspend dosing                                 Suspend dosing

Risk refers to acquiring infection during the immunodepletion phase. With postimmune reconstitution, the risk is low.

COVID‐19 = coronavirus disease 2019; EID = extended interval dosing; HSCT = hematopoietic stem‐cell transplant; N/A = not applicable; SID = standard interval dosing.

The immune mechanisms contributing to severe COVID‐19 include viral subversion of innate immunity and infection of macrophages,[^4^](#ana25770-bib-0004){ref-type="ref"} and, if similar to SARS‐CoV‐2, may trigger apoptosis of leucocytes leading to lymphopenia.[^5^](#ana25770-bib-0005){ref-type="ref"} The exact mechanisms are as yet unclear but suppression of innate responses due to modulation of IFN production or receptor signaling, and the apoptotic effects of virally encoded proteins have been proposed.[^6^](#ana25770-bib-0006){ref-type="ref"} Together, these allow widespread viral infection, excessive monocyte/macrophage activation, and, in severe cases, a cytokine storm triggering severe acute respiratory distress syndrome (ARDS). The viral‐specific CD8 T cell responses seem to eliminate SARS‐CoV‐2, whereas viral specific antibodies are probably more important to prevent reinfection and create long‐lasting immunity. A direct role of B cells in the destructive COVID‐19 pathology is unlikely because people with X‐linked agammaglobulinemia recover from the COVID‐19 pneumonia and lymphopenia without need of intensive care or oxygen ventilation.[^7^](#ana25770-bib-0007){ref-type="ref"} In MS, although a single case, ocrelizumab treatment did not augment or prolong COVID‐19 symptoms.[^8^](#ana25770-bib-0008){ref-type="ref"}

Because many of the MS DMTs have been designed to target the adaptive immune response; and for therapeutic effect most likely need to target the memory B cells,[^9^](#ana25770-bib-0009){ref-type="ref"} it is unlikely that MS DMTs treatment impact on the innate immune responses, although there is some evidence that fingolmod[^10^](#ana25770-bib-0010){ref-type="ref"} and alemtuzumab[^11^](#ana25770-bib-0011){ref-type="ref"} impact on the innate immune system. In addition, DMTs do not substantially limit the antibody responses to SARS‐CoV‐2 and, thus, do not pose a risk in the development of protective neutralizing antibody responses, however, some DMTs will blunt this.

To avoid "throwing the baby out with the bathwater" we recommend revision of the published guidelines[^2^](#ana25770-bib-0002){ref-type="ref"} in light of the role of the immune response in controlling SARS‐CoV‐2 infection (see Table [2](#ana25770-tbl-0002){ref-type="table"}), the emerging biology of COVID‐19, and accumulating case reports. We propose that although administration of some DMTs should be modified, others may well control the pathogenic immune responses during severe COVID‐19. For example, although the original guidelines that suggest anti‐CD20 therapies may increase the risk of infection,[12](#ana25770-bib-0012){ref-type="ref"}, [13](#ana25770-bib-0013){ref-type="ref"} this does not necessarily imply a greater risk of poor outcomes following infection. In addition, most MS‐related DMTs do not particularly target the innate immune system and few have any major long‐term impact on CD8 T cells to limit protection against COVID‐19, perhaps with the exception of alemtuzumab.[^14^](#ana25770-bib-0014){ref-type="ref"} Importantly, MS DMTs do not generally block immature B cell development, thus allowing antibody production preventing (re)infection, as well as response to vaccines when available. However, we recommend adjustments to dosing schedules to reduce the chance of infection.

Apart from the reactivation of herpes infections, the moderate immunosuppression obtained with most MS DMTs rarely leads to problems dealing with viral infections, even in the case of novel viral infections such as dengue fever.[^15^](#ana25770-bib-0015){ref-type="ref"} With the notable exception of progressive multifocal leukoencephalopathy (PML) and other rare central nervous system (CNS) viral infections in natalizumab treated patients, which can be de‐risked by adopting extended interval dosing,[^16^](#ana25770-bib-0016){ref-type="ref"} would indicate that the initiation and continuation of DMTs in MS does not pose an additional risk of developing more severe COVID‐19 to people with MS. However, immunosuppression to treat COVID‐19 has been proposed as a rational therapeutic approach.[17](#ana25770-bib-0017){ref-type="ref"}, [18](#ana25770-bib-0018){ref-type="ref"} This hypothesis is currently being tested in several trials to evaluate several immunosuppressive therapies for COVID‐19, which include fingolimod, an S1P modulator (NCT04280588) and IFNβ (NCT04343768, NCT04350671) that are widely used to treat MS. Although the information is only emerging, we anticipate that knowledge arising from registers collating data on people with MS, DMTs, and their responses to SARS‐CoV2 infection (e.g., NCT04354519) will support the hypothesis that moderate immunosuppression induced by the DMT used in MS may protect against the development of severe COVID‐19 infection, which is contrary to current opinion.

The accumulating real‐world data on the susceptibility of people with MS to develop severe COVID‐19 being treated with immunosuppressive therapies will allow us to accept or reject this hypothesis.
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